Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that new first-in-class treatments, including drugs from Vertex/GlaxoSmithKline, Rinat Neuroscience, Avigen, and Pharmos will expand the market to treat pain in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan to nearly $50 billion in 2020.

According to the new Pharmacor report Novel Approaches to Pain Therapy, the broad range of companies investigating novel pain therapeutics highlights the competition and commercial opportunity in this market in the wake of the withdrawal of two cyclooxygenase-2 (COX-2) inhibitors, Merck's Vioxx and Pfizer's Bextra.

The report finds that drugs with novel mechanisms of action such as Vertex/GlaxoSmithKline's VX-409 offer the greatest commercial reward with the lowest risk of failure. Additionally, Rinat Neuroscience's RN-624 and Avigen's AV-411 have the potential to become revolutionary pain therapies by offering improved efficacy over current therapies, although these agents also carry the greatest risk in development owing to the potential for significant side effects. The report also finds that Pharmos's PRS-211375 will become widely used to treat inflammatory pain.

"The dominance of well-established drug classes such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) is unlikely to change over the next 15 years despite the launch of ten novel drug classes in this market," said Amy Jassen, Ph.D., analyst at Decision Resources, Inc. "Instead, these novel drug classes will be used in subpopulations of pain patients or will be incorporated into existing treatment algorithms and combined with familiar therapies."

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Marketing Campaigns and Increasing Public Awareness Maintain Growth in the Minimally Invasive Surgery Spinal Fusion Market

View Now